Latest news with #OGN
Malaysian Reserve
29-05-2025
- Business
- Malaysian Reserve
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit
NEW YORK, May 29, 2025 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: CLASS PERIOD: October 31, 2024 to April 30, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Following this news, the price of Organon's common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon's stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day. DEADLINE: July 22, 2025 Shareholders should not delay in registering for this class action. Register your information here: NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of OGN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 22, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@ (646) 453-8903
Business Wire
29-05-2025
- Business
- Business Wire
Organon & Co. (OGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Organon & Co. ('Organon' or the 'Company') (NYSE: OGN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ORGANON & CO. (OGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company's dividend payout, from $0.28 to $0.02 and would 'redirect those funds to debt reduction.' On this news, Organon's stock price fell $3.48, or 26.9%, to close at $9.45 per share on May 1, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Organon securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
26-05-2025
- Business
- Business Wire
ORGANON SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC ('KSF') and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (NYSE: OGN), if they purchased the Company's securities between October 31, 2024 and April 30, 2025, inclusive (the 'Class Period'). This action is pending in the United States District Court for the District of New Jersey. What You May Do If you purchased securities of Organon and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( or visit to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by July 22, 2025. About the Lawsuit Organon and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On March 10, 2025, pre-market, the Company announced its financial results for the first quarter of 2025, disclosing, among other things, that management had reset the Company's dividend payout, from $0.28 to $0.02, contradicting its prior statements assuring investors that the regular quarterly dividend was a number one priority and that the Company was committed to its capital allocation strategy through the aforementioned dividend. On this news, the price of Organon's shares fell more than 27%, from a closing market price of $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025. The case is Hauser V. Organon & Co., et al., No. 25-cv-05322. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit
Yahoo
26-05-2025
- Business
- Yahoo
3 Low-Volatility Stocks with Questionable Fundamentals
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Choosing the wrong investments can cause you to fall behind, which is why we started StockStory - to separate the winners from the losers. That said, here are three low-volatility stocks to avoid and some better opportunities instead. Rolling One-Year Beta: 0.21 Best known for its Grown in Idaho brand, Lamb Weston (NYSE:LW) produces and distributes potato products such as frozen french fries and mashed potatoes. Why Do We Think Twice About LW? Demand is forecasted to shrink as its estimated sales for the next 12 months are flat Expenses have increased as a percentage of revenue over the last year as its operating margin fell by 5 percentage points Low free cash flow margin for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders At $50.56 per share, Lamb Weston trades at 14.7x forward P/E. If you're considering LW for your portfolio, see our FREE research report to learn more. Rolling One-Year Beta: 0.41 Owner of Spongebob Squarepants and formerly known as ViacomCBS, Paramount Global (NASDAQ:PARA) is a major media conglomerate offering television, film production, and digital content across various global platforms. Why Should You Sell PARA? Annual revenue declines of 2.3% over the last two years indicate problems with its market positioning Incremental sales over the last five years were much less profitable as its earnings per share fell by 22.1% annually while its revenue grew Diminishing returns on capital from an already low starting point show that neither management's prior nor current bets are going as planned Paramount's stock price of $11.99 implies a valuation ratio of 8x forward P/E. Dive into our free research report to see why there are better opportunities than PARA. Rolling One-Year Beta: 0.15 Spun off from Merck in 2021 to create a company dedicated to addressing unmet needs in women's health, Organon (NYSE:OGN) is a global healthcare company focused on improving women's health through prescription therapies, medical devices, biosimilars, and established medicines. Why Do We Avoid OGN? Customers postponed purchases of its products and services this cycle as its revenue declined by 3.8% annually over the last five years Earnings per share have contracted by 18% annually over the last four years, a headwind for returns as stock prices often echo long-term EPS performance Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 28.9 percentage points Organon is trading at $8.65 per share, or 2.2x forward P/E. Read our free research report to see why you should think twice about including OGN in your portfolio, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free.
Yahoo
20-05-2025
- Business
- Yahoo
Why Organon & Co.'s (OGN) Surged Last Week
We recently published a list of . In this article, we are going to take a look at where Organon & Co.'s (NYSE:OGN) stands against other stocks that surged yesterday. Wall Street's main indices were a mixed bag anew on Thursday, with the tech-heavy Nasdaq the sole loser, as investors continued to digest results of more corporate earnings and key economic data. The Nasdaq was down by 0.18 percent. In contrast, the Dow Jones grew by 0.65 percent while the S&P 500 rose by 0.41 percent. Beyond the major indices, 10 companies finished stronger on the back of impressive corporate earnings and planned mergers and acquisitions. In this article, we explore the specific reasons behind their surge. To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume. A pharmacist wearing a white lab coat and a face mask dispenses biosimilars at a pharmacy. Organon & Co. saw its share prices increase by 9.08 percent on Thursday to close at $8.77 apiece following news that it partnered with the Abu Dhabi Public Health Centre to enhance women's health. In a statement, the Abu Dhabi Public Health Centre said both entities will join forces to enhance women's health by focusing on key areas of intervention and addressing critical health challenges such as a healthy pregnancy, exchanging of knowledge and expertise in cardiovascular, reproductive, and maternal health, as well as improving healthcare. In the first quarter of the year, Organon & Co.'s (NYSE:OGN) net income declined by 57 percent to $87 million from $201 million in the same period last year, while revenues dipped by 7 percent to $1.5 billion from $1.6 billion year-on-year. The company also maintained its full-year 2025 revenue guidance, at a range of $6.125 billion to $6.325 billion. Overall, OGN ranks 4th on our list of stocks that surged last week. While we acknowledge the potential of OGN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than OGN but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Sign in to access your portfolio
